Has John Korman, MD received payments from drug or device companies?

Yes. Drug and device makers reported $4,180 in general payments to John Korman, MD across 178 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean John Korman, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about John Korman, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

John Korman, MD

Dermatology · Greer, SCNPI 1306166871

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,714 of the $4,180 with a category attached, or 88.8%. It is spread thinly across 21 manufacturers, the largest accounting for just 23.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,780, more than ten times the $149 reported in 2019. That places this record below the midpoint for dermatology clinicians in SC, where the typical reported total is $3,326.

$4,180in general payments, 2019–2025

Across 178 payments — averaging $23.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Johnson & Johnson$972
AbbVie$450
Sanofi$445
Hill Dermaceuticals, Inc.$293
Lilly USA, LLC$274
Incyte Corporation$259
plus $1K from 15 others

$207,539in research payments, 2019–2025

Across 37 payments — averaging $5609.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Sanofi US Services Inc.$154K
Pfizer$35K
Sun Pharmaceutical Industries Inc.$18K

What the payments were for

Food & beverage$3,71489%
Education$46611%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Johnson & Johnson(2 entities)	29	$972
AbbVie	21	$450
Sanofi	14	$445
Hill Dermaceuticals, Inc.	1	$293
Lilly USA, LLC	13	$274
Incyte Corporation	11	$259
Galderma Laboratories, L.p.	21	$220
E.r. Squibb & Sons, L.L.C.	16	$214
LEO Pharma Inc.	8	$175
Sun Pharmaceutical Industries Inc.	7	$173
Novartis	6	$143
Regeneron Healthcare Solutions, Inc.	4	$122
Pfizer	7	$103
Amgen	3	$73
UCB, Inc.	2	$69
Almirall LLC	2	$57
Arcutis Biotherapeutics, Inc.	2	$37
Boehringer Ingelheim	2	$34
Prugen, Inc. Pharmaceuticals	6	$31
Organon	2	$21
Ortho Dermatologics, A Division Of Bausch Health US, LLC	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Tolak$293
Tremfya$257
DUPIXENT$150
NEMLUVIO$111

How this compares

$4,180 in reported general payments places this provider in the 50th percentile of 203 dermatology providers in South Carolina.

See all dermatology providers in South Carolina →

Medicare billing

Part B allowed, 2024

$338,233

Medicare patients

1,250

Services billed

7,290

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Metronidazole	73	$3,404
Clobetasol Propionate	103	$3,157
Betamethasone Dipropionate	74	$2,592
Fluorouracil	29	$1,554
Mupirocin	245	$1,395
Triamcinolone Acetonide	170	$1,391
Ketoconazole	121	$1,379
Doxycycline Hyclate	79	$1,189
Tacrolimus	11	$907
Clindamycin Phosphate	33	$900
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc	72	$513
Ammonium Lactate	27	$419
Hydrocortisone	104	$362
Spironolactone	15	$338
Desonide	24	$332

Paid to pharmacies, not to this prescriber.

Other dermatology in Greer

Marshall ShulerGreenville$2.6M
Rebecca SmithFort Mill$2.3M
Todd SchlesingerCharleston$1.9M
Amylynne FrankelSpartanburg$987K
Marguerite GermainMt Pleasant$200K
George KeoughPawleys Island$150K
Christopher MartinAbbeville$129K
Lee CarsonGreenville$127K
Mark SiegelCharleston$120K
Jeffrey SmithWest Columbia$80K

See the full list for South Carolina →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →